Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01573611 · ClinicalTrials.gov registry record · Phase 1
Impact of Grape Consumption on Brain Metabolism and Cognitive Function
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01573611 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 12 participants.
The verdict
NCT01573611, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Constituents of grapes have been studied for their antioxidant, anti-inflammatory, and anticarcinogenic properties. In the past decade, there has been emerging evidence regarding a potential role for grapes in slowing cognitive decline and other effects of aging. Furthermore, evidence has been obtained in vivo that supplementation of aged rats with grape seed extract improves cognitive performance. Despite the promising accumulating data supporting the use of grapes as a safe and effective strategy for delaying the incidence of dementia, it remains unclear how grape intake would be useful with respect to factors such as dose schedule or stage of dementing illness. In general, well-controlled experimental data obtained in human subjects is in need of much further development. The investigators aim to measure effects of grape intake on cerebral metabolism and cognitive function, and to determine whether initial patterns, and magnitude of change, of cerebral metabolism assessed by positron emission tomography (PET) can serve respectively as a predictor of, and biomarker for, the magnitude of cognitive changes resulting from intake of grapes.
Interventions
- DIETARY_SUPPLEMENT Grape Powder
- DIETARY_SUPPLEMENT Placebo Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01573611
The ClinicalTrials.gov registry entry for NCT01573611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Grape Powder is the first listed.
NCT01573611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01573611 about?
NCT01573611 is a clinical study titled "Impact of Grape Consumption on Brain Metabolism and Cognitive Function". Constituents of grapes have been studied for their antioxidant, anti-inflammatory, and anticarcinogenic properties. In the past decade, there has been emerging evidence regarding a potential role for grapes in slowing cognitive decline and other effects of aging. Furthermore, evidence has been obtai...
What is the current status of trial NCT01573611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2012-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01573611?
The interventions under investigation include: Grape Powder (DIETARY_SUPPLEMENT), Placebo Powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01573611?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.